@CaryKelly11 @ToombsToni @jperky1956 No. It has been demonstrated that low LDL does not lead to cognitive decline. https://t.co/76fS2tKaEi https://t.co/ldIxXj9FmS
RT @drbrowncares: @PrevCardioOnc
@PrevCardioOnc
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
Fourier/Ebbinghaus - cognition in those with achieved LDL-C of <20 mg/dL https://t.co/48z8D4i2ut #cvlipids #CardioTwitter
Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/vityApf7Vo
RT @SABOURETCardio: #Cognition After Lowering #LDL With #Evolocumab #EBBINGHAUS Just keep in mind 3 factors : mean age of ASCVD patients wi…
RT @SABOURETCardio: #Cognition After Lowering #LDL With #Evolocumab #EBBINGHAUS Just keep in mind 3 factors : mean age of ASCVD patients wi…
RT @SABOURETCardio: #Cognition After Lowering #LDL With #Evolocumab #EBBINGHAUS Just keep in mind 3 factors : mean age of ASCVD patients wi…
RT @SABOURETCardio: #Cognition After Lowering #LDL With #Evolocumab #EBBINGHAUS Just keep in mind 3 factors : mean age of ASCVD patients wi…
RT @SABOURETCardio: #Cognition After Lowering #LDL With #Evolocumab #EBBINGHAUS Just keep in mind 3 factors : mean age of ASCVD patients wi…
#Cognition After Lowering #LDL With #Evolocumab #EBBINGHAUS Just keep in mind 3 factors : mean age of ASCVD patients with cognitive dysfunction at entry, FU duration, and brain regulation. No warning signal. #lipids https://t.co/uBymntT7DF
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
RT @ErinMichos: "The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an ave…
"The addition of #evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients who achieved LDL-C <20 mg/dl."
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
RT @drpablocorral: Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/eEJ4CS6s9C https://t.co/FOTOCg9PAa
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
RT @TripPrimaryCare: New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/5Lsq1yMYTO
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/5Lsq1yMYTO
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/5Lsq1yMYTO
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
New2Trip: Cognition After Lowering LDL-Cholesterol w/ Evolocumab https://t.co/RWEnKxQtdt
The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients who achieved LDL-C <20 mg/dl. Could anyone with an LDL-C < 20 survive COVID-
The first evidence to show the downside of excessive LDL-C lowering
RT @Drlipid: Reassuring - The addition of PCSK9i evolocumab to maximally tolerated statin Rx had no impact on patient-reported cognition af…
RT @Drlipid: Reassuring - The addition of PCSK9i evolocumab to maximally tolerated statin Rx had no impact on patient-reported cognition af…
RT @ATRIUMRx: ICYMI in @JACCJournals: additional evidence that LDL-lowering with evolocumab does not impair cognitive function: https://t.c…
RT @ATRIUMRx: ICYMI in @JACCJournals: additional evidence that LDL-lowering with evolocumab does not impair cognitive function: https://t.c…
RT @ATRIUMRx: ICYMI in @JACCJournals: additional evidence that LDL-lowering with evolocumab does not impair cognitive function: https://t.c…
RT @ATRIUMRx: ICYMI in @JACCJournals: additional evidence that LDL-lowering with evolocumab does not impair cognitive function: https://t.c…
RT @ATRIUMRx: ICYMI in @JACCJournals: additional evidence that LDL-lowering with evolocumab does not impair cognitive function: https://t.c…
RT @ATRIUMRx: ICYMI in @JACCJournals: additional evidence that LDL-lowering with evolocumab does not impair cognitive function: https://t.c…
ICYMI in @JACCJournals: additional evidence that LDL-lowering with evolocumab does not impair cognitive function: https://t.co/1KekioZqlt #CardioEd https://t.co/XEkq9DTp6p
Ecog scale: LDL even less than 20 mg/dl not diff from those above 100 mg/dl - interesting 🧐
Cognition After Lowering LDL-Cholesterol With Evolocumab https://t.co/zYeXp6I478
@INCAnursing
Cognition After Lowering LDL-Cholesterol With Evolocumab. J Am Coll Cardiol #Alzheimers https://t.co/xvb4j7nOu8
RT @ValleAlfonso: 👥22,655 ⏱2.2years #FOURIER ⚠️evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition…
RT @ValleAlfonso: 👥22,655 ⏱2.2years #FOURIER ⚠️evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition…
RT @drpablocorral: Do “physiological levels” of LDL-C affect cognition? 😉 @ProfKausikRay @pabeda1 @SABOURETCardio @Drlipid @LipidLover1030…
RT @ErinMichos: "The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an aver…
RT @erik_arnesen: Not even among patients who achieved LDL-C <20 mg/dl. 😯 https://t.co/2doqJLO0iS
RT @drpablocorral: Do “physiological levels” of LDL-C affect cognition? 😉 @ProfKausikRay @pabeda1 @SABOURETCardio @Drlipid @LipidLover1030…
RT @Drlipid: Reassuring - The addition of PCSK9i evolocumab to maximally tolerated statin Rx had no impact on patient-reported cognition af…
RT @ErinMichos: "The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an aver…
RT @ErinMichos: "The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an aver…
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…
RT @ValleAlfonso: 👥22,655 ⏱2.2years #FOURIER ⚠️evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition…
RT @ValleAlfonso: 👥22,655 ⏱2.2years #FOURIER ⚠️evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition…
Not even among patients who achieved LDL-C <20 mg/dl. 😯
Seguridad de Evolocumab aún con niveles bajos de LDLc
RT @ErinMichos: "The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an aver…
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…
Don’t be afraid to lower your LDL-cholesterol when needed.
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…
#lipids @ANazmiCalik @AngoulvantD @garand_f @GiuseppeGalati_ @mirvatalasnag @DocSavageTJU @fischman_david @DavidWienerMD @cardioPCImom @ajaykishore82 @MeralKayikcoglu @cardioPCImom . No warning signal in young p (age 62 y) with normal cognitive status at e
More data from Fourier & Ebbinghaus showing a super low LDL cholesterol has no impact on cognition even among patients who achieved LDL-C <20 mg/dl.
RT @ValleAlfonso: 👥22,655 ⏱2.2years #FOURIER ⚠️evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition…
RT @JACCJournals: Does super-low LDL-C affect cognition? Dr. @rgiugliano et al. provide an analysis of the FOURIER trial in this week's #JA…